Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atai Life Sciences N.V.
(NQ:
ATAI
)
1.100
+0.020 (+1.85%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Atai Life Sciences N.V.
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes
October 07, 2024
Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential.
Via
Benzinga
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
October 04, 2024
Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options.
Via
Benzinga
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
September 15, 2024
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.
Via
Talk Markets
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
September 12, 2024
Via
Benzinga
Exposures
Product Safety
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
September 10, 2024
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are...
Via
Talk Markets
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
September 06, 2024
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a...
Via
Talk Markets
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
September 05, 2024
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
August 24, 2024
Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past...
Via
Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
August 15, 2024
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest...
Via
Talk Markets
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
August 14, 2024
Atai Life Sciences reports positive early data for its DMT-based depression treatment, VLS-01, and plans a Phase II trial targeting treatment-resistant patients.
Via
Benzinga
ATAI Stock Earnings: ATAI Life Sciences Misses EPS for Q2 2024
August 13, 2024
ATAI stock results show that ATAI Life Sciences missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
July 31, 2024
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.
Via
Benzinga
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
July 14, 2024
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...
Via
Talk Markets
3 Dirt-Cheap Drug Developers With Blockbuster Potential
July 11, 2024
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.
Via
InvestorPlace
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
July 08, 2024
These psychedelic drug stocks aren't as radical as once thought as institutional awareness and emphasize on their potential increases.
Via
InvestorPlace
3 Psychedelic Stocks to Ride to the Moon and Beyond
July 06, 2024
Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market.
Via
InvestorPlace
Exposures
Product Safety
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
July 03, 2024
Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks.
Via
InvestorPlace
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
July 02, 2024
These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns.
Via
InvestorPlace
Clinical-Stage BioTech Drug Stocks Declined 13% In June
July 01, 2024
Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read
Via
Talk Markets
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
June 22, 2024
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...
Via
Talk Markets
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
June 09, 2024
Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA.
Via
Talk Markets
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
June 05, 2024
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.
Via
Benzinga
Exposures
Product Safety
What's Going On With MindMed And Psychedelic Stocks?
June 05, 2024
Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD)....
Via
Benzinga
ATAI Stock Earnings: ATAI Life Sciences Beats EPS for Q1 2024
May 15, 2024
ATAI stock results show that ATAI Life Sciences beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
May 13, 2024
Via
Talk Markets
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
May 09, 2024
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
May 05, 2024
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.
Via
Talk Markets
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
April 23, 2024
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and...
Via
Talk Markets
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
April 19, 2024
Via
Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
April 17, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.